Catalent, Novo Nordisk and FTC
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Paul Harris of Harris Douglas Asset Management says he hasn’t sold a stock since 2020. ‘I don’t feel the need to sell ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
In a report released on October 15, David Evans from Kepler Capital maintained a Hold rating on Novo Nordisk (0QIU – Research Report), ...
Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback